CRBU — Caribou Biosciences, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2021-07-23.
Performance
Technicals
Others in Healthcare
Measured signals that fired on CRBU
| date | signal | measured base rate |
|---|---|---|
| 2026-08-03 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
| 2026-07-31 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
| 2026-06-18 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
| 2026-05-27 | Equal highs taken out structure | -0.70% over 21 days · t = -8.28 · n = 68,636 statistically distinguishable from its control group |
| 2026-04-17 | Equal highs taken out structure | -0.70% over 21 days · t = -8.28 · n = 68,636 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-02-25 | Kelly Timothy P Chief Technology Officer | Open-market sale | 6.2K | 1.93 | 12.0K |
| 2026-02-24 | Khan Ruhi Ahmad Chief Business Officer | Open-market sale | 6.9K | 1.96 | 13.6K |
| 2026-02-24 | MCCLUNG BARBARA G Chief Legal Officer | Open-market sale | 6.9K | 1.96 | 13.6K |
| 2026-02-24 | Kelly Timothy P Chief Technology Officer | Open-market sale | 3.1K | 1.96 | 6.2K |
| 2026-02-24 | Albertson Tina M. Chief Medical Officer | Open-market sale 10b5-1 plan | 1.1K | 1.96 | 2.1K |
| 2026-02-20 | Albertson Tina M. Chief Medical Officer | Grant or award 10b5-1 plan | 55.0K | 0.00 | 0 |
| 2026-02-20 | Haurwitz Rachel E. President and CEO | Grant or award | 151.7K | 0.00 | 0 |
| 2026-02-20 | Khan Ruhi Ahmad Chief Business Officer | Grant or award | 45.0K | 0.00 | 0 |
| 2026-02-20 | MCCLUNG BARBARA G Chief Legal Officer | Grant or award | 45.0K | 0.00 | 0 |
| 2026-02-20 | Kelly Timothy P Chief Technology Officer | Grant or award | 45.0K | 0.00 | 0 |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| Pfizer Inc | 8.3M | 4.7M |
| VANGUARD CAPITAL MANAGEMENT LLC | 7.2M | 3.8M |
| RENAISSANCE TECHNOLOGIES LLC | 4.9M | 2.6M |
| Kynam Capital Management, LP | 4.8M | 2.5M |
| BlackRock, Inc. | 4.1M | 2.1M |
| TWO SIGMA INVESTMENTS, LP | 3.3M | 1.8M |
| BANK OF AMERICA CORP /DE/ | 2.5M | 1.3M |
| Aberdeen Group plc | 2.3M | 1.2M |
| MARSHALL WACE, LLP | 2.3M | 1.2M |
| MILLENNIUM MANAGEMENT LLC | 2.0M | 1.1M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Caribou Biosciences, Inc. (CRBU) filed form 8-K · 2026-08-13 · SEC EDGAR
Ask the AI about CRBU
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →